Program
omfiloctocog alfa
Also written as “Recombinant Human Coagulation FVIII”, “SCT800” and “SCT800 prophylaxis and treatment for bleeding events”.
Its studies are mostly in Hemophilia A, led by Sinocelltech Group.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sinocelltech Group | 62 open or running | phase 4since May 9, 2019 | Aug 30, 2016 | Dec 26, 2028phase 3 · NCT07437404 |
Also a collaborator on its studies: Parexel and Q2 Solutions.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 30, 2016First study: phase 1 study in Hemophilia AFirst studyNCT02888223 · 16 enrolled · China
- Sep 28, 2016Phase 3 study in Hemophilia ANCT02921945 · 50 enrolled · China
- Jan 17, 2019Phase 3 study in Hemophilia ANCT03815318 · 73 enrolled · China
- May 9, 2019Phase 4 study in Hemophilia ANCT03947567 · 240 planned · China
- May 9, 2019Phase 3 study in Hemophilia ANCT03947320 · 70 enrolled
- Feb 9, 2026Phase 3 study in Hemophilia ANCT07437404 · 36 planned · China
Ahead
- Dec 26, 2028Primary completion: phase 3 study in Hemophilia ANCT07437404
TargetBeta
“Coagulation factor VIII exogenous protein”ChEMBL 37, by rule
Other programs on F8
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| antihemophilic factor, human recombinantrule | Takeda | phase 4 | 16 |
| efanesoctocog alfarule | Sanofi | phase 4 | 12 |
| lonoctocog alfarule | CSL | phase 3 | 4 |
Studies
All 6 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07437404Hemophilia A · China | 3 | Recruiting | Dec 26, 2028 | 36 |
| NCT03947567Hemophilia A · China | 4 | Recruiting | Apr 1, 2025 | 240 |
| NCT03947320Hemophilia A | 3 | UNKNOWN | Sep 20, 2020 | 70 |
| NCT03815318Hemophilia A · China | 3 | Completed | Jan 16, 2020 | 73 |
| NCT02921945Hemophilia A · China | 3 | UNKNOWN | Dec 2017 | 50 |
| NCT02888223Hemophilia A · China | 1 | UNKNOWN | Feb 2017 | 16 |
How it is read
Names in the registry
- “Recombinant Human Coagulation FVIII”, 3 entries
- “SCT800”, 2 entries
- “SCT800 prophylaxis and treatment for bleeding events”, 1 entry
Codes read as this program: SCT800.
Conditions, from the studies’ own filings
- Hemophilia A, 6 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.